other·
Experimental Tuberculosis Vaccine Fell Short of BCG in Nearly Seven Thousand African Newborns but Questions Remain
The phase 3 priMe trial found that VPM1002 was not noninferior to BCG in nearly 7,000 newborns, but the result is hard to interpret.
The phase 3 priMe trial found that VPM1002 was not noninferior to BCG in nearly 7,000 newborns, but the result is hard to interpret.
Read original at Medical Daily